Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most

Document Details

Document Type
Pub Defense Publication
Publication Date
May 01, 2018
Source ID
10.1016/j.bbmt.2018.02.006

Entities

People

  • Ann Woolfrey
  • Brent R. Logan
  • Bronwen E Shaw
  • Carolyn Hurley
  • David Porter
  • Effie W Petersdorf
  • Hailin Wang
  • James Robinson
  • Jason Dehn
  • Joseph Pidala
  • Juliet Barker
  • Katharina Fleischhauer
  • Katharine C Hsu
  • Martin Maiers
  • Mary M. Horowitz
  • Michael R Verneris
  • Mike Haagenson
  • Stephanie J. Lee
  • Stephen R. Spellman
  • Steven G.e. Marsh

Organizations

  • Amgen
  • Angiocrine Bioscience (United States)
  • Astellas Pharma (United States)
  • AstraZeneca (United States)
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb
  • Celgene
  • Chiron Corporation
  • Fred Hutchinson Cancer Center
  • Genzyme
  • Gilead Sciences
  • Health Resources and Services Administration
  • Incyte
  • Janssen Scientific Affairs (United States)
  • Jazz Pharmaceuticals
  • Karyopharm Therapeutics (United States)
  • Kite Pharma
  • Medical College of Wisconsin
  • Merck & Co.
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Marrow Donor Program
  • Office of Naval Research
  • Patient-Centered Outcomes Research Institute
  • Pfizer
  • Seagen
  • Shire plc
  • St. Baldrick's Foundation
  • Swedish Orphan Biovitrum
  • Takeda Oncology
  • United States Public Health Service
  • University of Minnesota